Alumis is a pre-commercial biotech whose investment case rests entirely on a single pipeline candidate while burning cash at a rate far exceeding revenue; although price momentum is constructive and analyst price targets imply substantial upside, deep quality concerns — no competitive moat, a failing financial-health screen, and extreme bearish positioning in both the short book and options market — place this firmly in speculative territory pending clinical proof.
Thesis pillars
- Single Pipeline Concentration Risk→Stable
- Cash Burn No Moat Quality Failure→Stable
- Recent Earnings Beat Inflection→Stable
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Mar 19, 2026
Alumis Inc. (ALMS) Stock Analysis
Recovery setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $7.13: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.2/10. Specifically: High short interest: 13%; Below-average business quality; Below long-term trend.
Alumis is a clinical-stage biopharmaceutical company developing envudeucitinib (envu), a TYK2 inhibitor, for plaque psoriasis and lupus, with an NDA submission planned for H2 2026 following positive Phase 3 ONWARD data in Q1 2026. The company has no revenue, reported a $243.3... Read more
Sell if holding. Engine safety override at $7.13: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.2/10. Specifically: High short interest: 13%; Below-average business quality; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 52. Score 4.2/10, moderate confidence.
Passes 7/9 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 15d clear, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
About Alumis Inc.
About Alumis Inc.
Alumis reported positive topline results from its Phase 3 ONWARD1 and ONWARD2 trials evaluating envudeucitinib (envu) in moderate-to-severe plaque psoriasis in January 2026, with envu meeting all primary and secondary endpoints in both studies. On average, 74% of patients achieved PASI 75 and 59% achieved sPGA 0/1 at Week 16; the company plans to submit an NDA to the FDA in the second half of 2026. At December 31, 2025, Alumis had an accumulated deficit of $901.9 million with no products approved for commercial sale.
Alumis has no revenue and funds operations through equity offerings; in March 2026, the company entered a Controlled Equity Offering agreement with Cantor Fitzgerald for up to $300.0 million. Net losses were $243.3 million in 2025 and $294.2 million in 2024. Two TYK2 inhibitors comprise the company's clinical pipeline: envu (allosteric inhibitor) in Phase 3 for plaque psoriasis and in Phase 2b for systemic lupus erythematosus — the LUMUS trial, with topline data expected in Q3 2026 — and A-005, a CNS-penetrant TYK2 inhibitor in Phase 1, targeting multiple sclerosis and neuroinflammatory diseases. Through the ACELYRIN Merger completed May 21, 2025 (a common stock transaction valued at approximately $238.1 million), the company also acquired lonigutamab, a subcutaneous monoclonal antibody targeting IGF-1R for thyroid eye disease, which remains under evaluation. Manufacturing is outsourced to contract manufacturing organizations; the filing identifies CMO performance and cGMP compliance as a supply continuity risk.
Show full overview
The company's path to profitability, per the 10-K, is dependent upon obtaining regulatory approval for and successfully commercializing envu. A second binary readout risk is the LUMUS Phase 2b trial in SLE, with topline data expected in Q3 2026; success could meaningfully expand the addressable market beyond psoriasis, while failure could limit commercial scope to a single indication. The lonigutamab TED program represents a third contingent value driver, though the filing notes lonigutamab's potential to improve on the sole currently-approved TED therapy remains unproven.
See also: Healthcare · Biotechnology
From Alumis Inc.'s most recent 10-K filing, extracted June 9, 2026.
Recent developments
updated 2026-10-29Recent Developments — Alumis Inc.
Latest news
- NEWS Alumis New Phase 3 ONWARD Data Show Envudeucitinib Improved Scalp, Itch And Quality Of Life In Psoriasis, Building On 54 — benzinga Oct 9, 2026 positive
- NEWS Guggenheim Downgrades Alumis to Neutral — benzinga Sep 3, 2026 negative
- NEWS Oppenheimer Maintains Outperform on Alumis, Lowers Price Target to $37 — benzinga Sep 2, 2026 positive
- NEWS Wells Fargo Maintains Overweight on Alumis, Lowers Price Target to $25 — benzinga Sep 2, 2026 neutral
- NEWS Sirius XM, Dell, Ollie's Bargain Outlet And Other Big Stocks Moving Higher On Wednesday — benzinga Sep 2, 2026 positive
Generated 2026-10-29T00:28:48Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineenvu (envudeucitinib)10-K Item 1A: 'Our ability to achieve profitability in the future is dependent upon obtaining regulatory approval for and successfully commercializing our most advanced candidate, envu'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers
Revenue shrinking — -37.7% YoY. Growth thesis broken unless recovery story develops.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $7.13: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.2/10. Specifically: High short interest: 13%; Below-average business quality; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 52. Prior stop was $6.63. Score 4.2/10, moderate confidence.
Resistance target: $7.33 (+2.8% upside). Prior stop was $6.63. Stop-loss: $6.63.
Concentration risk — Pipeline: envu (envudeucitinib); DATA_ISSUE: analyst_target_implausible (raw $31.12 vs price $7.13 — ratio 4.4×). Rejected, falling back to technical TP.; Quality below floor (3.2 < 4.0).
Alumis Inc. trades at a P/E of N/A (forward -2.3). TrendMatrix value score: 5.0/10. Verdict: Sell.
16 analysts cover ALMS with a consensus score of 4.3/5. Average price target: $31.
What does Alumis Inc. do?Alumis is a clinical-stage biopharmaceutical company developing envudeucitinib (envu), a TYK2 inhibitor, for plaque...
Alumis is a clinical-stage biopharmaceutical company developing envudeucitinib (envu), a TYK2 inhibitor, for plaque psoriasis and lupus, with an NDA submission planned for H2 2026 following positive Phase 3 ONWARD data in Q1 2026. The company has no revenue, reported a $243.3 million net loss in 2025, and an accumulated deficit of $901.9 million, with A-005 (CNS TYK2) and lonigutamab (TED) in earlier development.